Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
Recruiting in Palo Alto (17 mi)
+18 other locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: XOMA (US) LLC
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.
Research Team
Eligibility Criteria
Inclusion Criteria
Diagnosis of moderate to severe acne vulgaris
Acne vulgaris unresponsive to oral antibiotics
Willingness to maintain current habits for facial cleaning, shaving, and application of cosmetics through the end of the study
Treatment Details
Interventions
- gevokizumab (Monoclonal Antibodies)
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: low dose gevokizumabExperimental Treatment1 Intervention
Group II: high dose gevokizumabExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
NCT01498874Houston, TX
NCT01498874Austin, TX
NCT01498874Albuquerque, NM
NCT01498874High Point, NC
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
XOMA (US) LLC
Lead Sponsor
Trials
28
Patients Recruited
2,100+